Panacea Journal of Medical Sciences

---

A comparative study to see the result of remdesevir in moderate and severe patients of covid 19

Full Text PDF Share on Facebook Share on Twitter

---

Original Article

Author Details : Huma Firdaus*, Nafees Ahmad Khan, Naila Ambrin, Arushi Verma, Maqsumi Reza, Mohammad Shameen, Rakesh Bhargava

Volume : 13, Issue : 3, Year : 2023

Article Page : 731-735

https://10.18231/j.pjms.2023.134

Suggest article by email

---

Abstract

Introduction : Till date for covid 19 infection no specific drug has been developed. This study was taken up to see the effect of remdesevir in moderate and severe covid cases.
Materials and Methods: 22 diagnosed patients of covid 19 in moderate and severe category were included in the study and divived in two groups of 11 patients each. Group a received only symptomatic treatment and other group B received injection remdesevir for 5 days along with symptomatic treatment.
Results : Total 13 male (7 in group A; 6 in group B) and 9 female (4 in group A; 5 in group A) patients were included in the study. Patients in group B receiving injection remdesevir had shortened hospital stay, early symptom improvement and less mortality than those receiving only symptomatic treatment.
Conclusion : With no definite drug till date we conclude that remdesevir could be used as a good alternative treatment in moderate and severe category patients of covid 19.
 
Keywords : COVID 19, Remdesevir, Moderate and severe COVID 19 patients

How to cite : Firdaus H, Khan N A, Ambrin N, Verma A, Reza M, Shameen M, Bhargava R, A comparative study to see the result of remdesevir in moderate and severe patients of covid 19. Panacea J Med Sci 2023;13(3):731-735

Copyright © 2023 by author(s) and Panacea J Med Sci. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License (creativecommons.org)